Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules

The present invention is a pharmaceutical composition comprising a targeted tissue specific antigen binding molecules, non-natural compounds antigens that the antigen-binding activity varies with the concentration of binding molecules, each different plurality of the antigen binding libraries, including the molecular art antigen-binding molecule, and that a task of providing a method of manufacturing the same, and the method for screening for antigen-binding molecules. The present inventors have found that, depending on the concentration of the low molecular weight compound and creating an antigen binding molecule comprising the antigen-binding domain or an antigen-binding domain that binding activity to the antigen changes, and further has respective different plurality of the antigen binding domain, or an antigen-binding domain by creating a library that contains a and found that the above problems can be solved by using the library. To cure various diseases resulting from the target tissue to target tissue-specific by use of antigen-binding molecules of the invention can be performed.

[1]  A. Grossman,et al.  Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. , 2012, European journal of endocrinology.

[2]  T. Takeuchi,et al.  The Japanese experience with biologic therapies for rheumatoid arthritis , 2010, Nature Reviews Rheumatology.

[3]  Stephen C Alley,et al.  Antibody-drug conjugates: targeted drug delivery for cancer. , 2010, Current opinion in chemical biology.

[4]  M. Friedrich,et al.  T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells , 2010, Proceedings of the National Academy of Sciences.

[5]  R. Landewé,et al.  Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA , 2010, Annals of the rheumatic diseases.

[6]  Louis M. Weiner,et al.  Monoclonal antibodies: versatile platforms for cancer immunotherapy , 2010, Nature Reviews Immunology.

[7]  P. Kufer,et al.  BiTE: Teaching antibodies to engage T-cells for cancer therapy. , 2009, Current opinion in molecular therapeutics.

[8]  H. Riechelmann,et al.  Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. , 2008, Oral oncology.

[9]  G. A. Lazar,et al.  Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. , 2007, Drug discovery today.

[10]  S. Iida,et al.  Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies , 2006, Expert opinion on biological therapy.

[11]  Janice M Reichert,et al.  Monoclonal antibody successes in the clinic , 2005, Nature Biotechnology.

[12]  Hyo Jeong Hong,et al.  Antibody engineering for the development of therapeutic antibodies. , 2005, Molecules and cells.

[13]  A. Pavlou,et al.  The therapeutic antibodies market to 2008. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[14]  P. Carter,et al.  Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies , 1993, Cancer Immunology, Immunotherapy.